MedWatch

Pfizer to quadruple Covid-19 vaccine price in US

When Pfizer’s current agreement with the US health authorities expires, the pharmaceutical firm plans to quadruple the price of its Covid-19 vaccine.

Pfizer is planning to increase the price of its Covid-19 vaccine to USD 110-130 in the US when its current agreement in the country expires, Reuters reports. This is four times the current price.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs